Drug Development Laboratories Pharma Companies 
Drug Patent Watch
JANUARY 9, 2025
Navigating the complex landscape of drug development and manufacturing can be a daunting task. Enter the Contract Development and Manufacturing Organization (CDMO) a lifeline for many startups looking to bring their innovative therapies to market.
Reprocell
NOVEMBER 1, 2022
Pharma companies are legally required to test novel drugs in animal models before beginning human trials. And while animal testing has progressed thousands of therapeutics that we use today, it is not without its experimental and ethical downfalls.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Connected Lab
APRIL 8, 2020
How is AI being applied in Drug Discovery efforts? It is reported that every one of the major pharmaceutical companies has announced a partnership with at least one AI-based drug development company, but how is AI being used to facilitate drug development? Nature , vol. RARE Facts.” Smith, Simon. “36
DrugBank
JUNE 27, 2024
Generic drugs are also an interesting case and are common targets for repurposing due to their established safety profiles and long market presence. They also provide a level playing field for academics, biotech companies, and pharma giants to compete on.
DrugBaron
JULY 19, 2022
Constructing larger and more diverse screening libraries was, for a while, the competitive advantage of the largest pharma companies. Around the turn of the century, increases in computing capabilities opened up an opportunity to expand the search space by several more orders of magnitude, with the arrival of in silico screening.
Vial
MARCH 1, 2024
billion in 2023 attributable to its laboratory products and biopharma services segment (53.8% By type of service, clinical research services accounted for the lion’s share of the North American CRO services market, followed by early-phase development services, laboratory services, and consulting services. US), IQVIA Inc.
Predictive Oncology
FEBRUARY 7, 2023
That means a lot of wasted effort and resources for drugmakers given that even before a molecule enters Phase I trials, typically five to eight years of development have already been invested in the product. The next step was to validate the predictions and learn whether the drugs really produce a response in the specific tumor type.
Expert insights. Personalized for you.
52 
Let's personalize your content